Client News

STORM Therapeutics presents breakthrough data showing in vivo efficacy and therapeutic proof of concept for targeting RNA modifying enzymes

Client News

Data to be presented at inaugural STORM Therapeutics RNA Epigenetics in Human Disease Conference in Cambridge, UK 18 September 2019, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the … Continue reading “STORM Therapeutics presents breakthrough data showing in vivo efficacy and therapeutic proof of concept for targeting RNA modifying enzymes”

By Optimum

Theragnostics signs agreement with Astrazenenca

Client News

Enables development of first-in-class molecular radiotherapy based on PARP inhibitor Offers significant potential for diagnosing and treating a broad range of cancers LONDON, UK, 05 September 2019 – Theragnostics, which … Continue reading “Theragnostics signs agreement with Astrazenenca”

By Optimum

iSTAR Medical announces EUR 40m Series C Financing

Client News

To accelerate development and commercialisation of innovative Glaucoma MIGS device, MINIjectTM WAVRE, Belgium — 5 September 2019: iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the … Continue reading “iSTAR Medical announces EUR 40m Series C Financing”

By Optimum

ImaginAb to Present at Upcoming Investor and Scientific Conferences in September & October 2019

Client News

Los Angeles, September 4, 2019 – ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces that it is scheduled to attend and / or present at the following investor and scientific … Continue reading “ImaginAb to Present at Upcoming Investor and Scientific Conferences in September & October 2019”

By Optimum

Positive feedback from FDA significantly benefits ongoing NefIgArd pivotal Phase 3 study

Client News

Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that it has obtained written feedback from the US Food and Drug Administration (FDA) that will have a significant impact on the ongoing … Continue reading “Positive feedback from FDA significantly benefits ongoing NefIgArd pivotal Phase 3 study”

By Optimum

Forendo Pharma commences Phase 1b Proof of Mechanism study with its lead endometriosis program, HSD17B1 inhibitor FOR-6219

Client News

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces initiation of dosing in a Phase 1b clinical study in its lead endometriosis … Continue reading “Forendo Pharma commences Phase 1b Proof of Mechanism study with its lead endometriosis program, HSD17B1 inhibitor FOR-6219”

By Optimum

STORM Therapeutics to Host First RNA Epigenetics Conference in Cambridge UK

Client News

20 August 2019, Cambridge, UK: STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapeutics modulating RNA epigenetics, today announced that it will be hosting an … Continue reading “STORM Therapeutics to Host First RNA Epigenetics Conference in Cambridge UK”

By Optimum

Strategic In-Licensing Related to Autoimmune Hepatitis in the US Market

Client News

Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that it has exclusively in-licensed Budenofalk 3mg oral capsule for the US market from the German pharmaceutical company Dr. Falk Pharma GmbH (“Dr. … Continue reading “Strategic In-Licensing Related to Autoimmune Hepatitis in the US Market”

By Optimum

IXICO Provides an Update on New and Current Contracts

Client News

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces an update on contracts: · Two new biopharmaceutical client contracts with combined value of over £1m · Award of … Continue reading “IXICO Provides an Update on New and Current Contracts”

By Optimum

Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD

Client News

LONDON, Aug. 05, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a … Continue reading “Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD”

By Optimum

One Nucleus Strengthens Board with Appointment of New Director

Client News

Life Sciences industry company operations and communications expert joins the region’s Life Science & Healthcare membership organisation One Nucleus, the Cambridge based not-for-profit membership organisation for the East of … Continue reading “One Nucleus Strengthens Board with Appointment of New Director”

By Optimum

Neuraxpharm Launches First Products in the United Kingdom

Client News

Neuraxpharm launches its first products in the United Kingdom Craig Bowen appointed as General Manager of Neuraxpharm UK -PRESS RELEASE- July 31, 2019 Neuraxpharm Group, a leading European specialty pharmaceutical … Continue reading “Neuraxpharm Launches First Products in the United Kingdom”

By Optimum

ImaginAb Initiates Phase II Clinical Trial at a World-Leading Cancer Center

Client News

Los Angeles, July 24, 2019 – ImaginAb Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Dana-Farber Cancer … Continue reading “ImaginAb Initiates Phase II Clinical Trial at a World-Leading Cancer Center”

By Optimum

Novo Holdings REPAIR Impact Fund invests USD 10 million in Curza and Spero

Client News

REPAIR Impact Fund makes two investments after US/Canadian investment round, totaling USD 10 million. The Fund has now invested a total of USD 30 million in six companies. Copenhagen, Denmark, … Continue reading “Novo Holdings REPAIR Impact Fund invests USD 10 million in Curza and Spero”

By Optimum

Sunstone Life Science Ventures joins Forendo Pharma Investor Syndicate

Client News

Sunstone Life Science Ventures joins Forendo Pharma Investor Syndicate Date: July 19, 2019 | author: Forendo Pharma Forendo Pharma, a clinical stage drug development company focusing on novel treatments in … Continue reading “Sunstone Life Science Ventures joins Forendo Pharma Investor Syndicate”

By Optimum

Gilead and Galapagos Enter Into Transformative Research and Development Collaboration

Client News

14 July 2019 at 19:00 CET – Gilead to Make $3.95 Billion Upfront Payment and $1.1 Billion Equity Investment – – Gilead Gains Access to Galapagos’ Differentiated Drug Discovery Platform and Current … Continue reading “Gilead and Galapagos Enter Into Transformative Research and Development Collaboration”

By Optimum

vasopharm Closes €9.5 million Financing Round

Client News

Würzburg, Germany – July 11, 2019: vasopharm GmbH, a private biopharmaceutical company developing a novel treatment for traumatic brain injury (TBI), today announced the successful completion of a €9.5 million … Continue reading “vasopharm Closes €9.5 million Financing Round”

By Optimum

NeoPhore appoints Dr Matthew Baker as VP Immunology

Client News

08 July 2019, Cambridge, UK – NeoPhore Limited, a small molecule cancer immuno-oncology company, today announces the appointment of Dr Matthew Baker as VP Immunology to the company’s management team. … Continue reading “NeoPhore appoints Dr Matthew Baker as VP Immunology”

By Optimum

STORM Therapeutics appoints Dr John Haurum to the Board of Directors

Client News

27 June 2019, Cambridge, UK: STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced the appointment of Dr John Haurum … Continue reading “STORM Therapeutics appoints Dr John Haurum to the Board of Directors”

By Optimum